Advanced-stage cHL: Rethinking Our Options in Frontline Therapy

Advanced-stage cHL: Rethinking Our Options in Frontline Therapy
Advanced-stage cHL: Rethinking Our Options in Frontline Therapy
CME, CPE
Jonathon B. Cohen, MD, MS
Release Date: October 17, 2018
Expiration Date: October 17, 2019
New strategies are emerging to improve the frontline treatment of patients with newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL). In this interview, Dr. Jonathon Cohen discusses results from recent clinical trials that are making an impact on the frontline management of advanced-stage cHL. He also outlines how these advances will influence clinical practice and positively impact current standards of care for the disease.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics, Inc.
View Only, CE ExpiredView Only, No CreditGet Certificate
 

MediCom Worldwide, Inc. would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support. To better serve the needs of our audience, ManagingHodgkinLymphoma.com is now ManagingLymphoma.com

©2019 MediCom Worldwide, Inc. All rights reserved